(NASDAQ: FULC) Fulcrum Therapeutics's forecast annual revenue growth rate of 25.04% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Fulcrum Therapeutics's revenue in 2025 is $80,000,000.On average, 1 Wall Street analysts forecast FULC's revenue for 2028 to be $633,717,052, with the lowest FULC revenue forecast at $633,717,052, and the highest FULC revenue forecast at $633,717,052. On average, 1 Wall Street analysts forecast FULC's revenue for 2029 to be $1,314,935,894, with the lowest FULC revenue forecast at $1,314,935,894, and the highest FULC revenue forecast at $1,314,935,894.
In 2030, FULC is forecast to generate $2,763,740,467 in revenue, with the lowest revenue forecast at $2,763,740,467 and the highest revenue forecast at $2,763,740,467.